A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease

19972,375 citationsJournal Articlebronze Open Access

Authors

Mary Sano · New York University

Christopher Ernesto · Alzheimer’s Disease Neuroimaging Initiative

Ronald G. Thomas · Alzheimer’s Disease Neuroimaging Initiative

Melville R. Klauber · University of California, San Diego

Kimberly Schafer · Alzheimer’s Disease Neuroimaging Initiative

Michael Grundman · Alzheimer’s Disease Neuroimaging Initiative

Peter Woodbury

Abstract

In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.

Topics & Keywords

Cholinesterase and Neurodegenerative Diseases Antioxidant Activity and Oxidative Stress Alzheimer's disease research and treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 336, Issue 17, pp. 1216-1222

DOI: 10.1056/nejm199704243361704

Field-Weighted Citation Impact: 116.81